Yinhu Qingwen Granula for the Treatment of Severe CoVID-19
Status:
Suspended
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of
pneumonia caused by CoVID-19, and the number of cases of infection with CoVID-19 identified
in Wuhan increased markedly over the later part of January 2020, with cases identified in
multiple other Provinces of China and internationally.Given no specific antiviral therapy for
CoVID-19 infection and the availability of Yinhu Qingwen Granula as a potential antiviral
Chinese medicine based on vivo antiviral studies in CoVID-19, this adaptive,
randomized,double-blind,controlled trial will evaluate the efficacy and safety of Yinhu
Qingwen Granula in patients hospitalized with severe CoVID-19.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Zhong Wang
Collaborators:
Jizhong Energy Fengfeng Group Hospital North China University of Science and Technology Affiliated Hospital Tanshan People's Hospital The First Affiliated Hospital of Dalian Medical University Wuhan Leishenshan Hospital